MA39170B1 - Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer - Google Patents

Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer

Info

Publication number
MA39170B1
MA39170B1 MA39170A MA39170A MA39170B1 MA 39170 B1 MA39170 B1 MA 39170B1 MA 39170 A MA39170 A MA 39170A MA 39170 A MA39170 A MA 39170A MA 39170 B1 MA39170 B1 MA 39170B1
Authority
MA
Morocco
Prior art keywords
serine
cancer
treatment
threonine kinase
inhibitory compounds
Prior art date
Application number
MA39170A
Other languages
English (en)
Other versions
MA39170A1 (fr
Inventor
Aleksandr Kolesnikov
Steven Do
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA39170A1 publication Critical patent/MA39170A1/fr
Publication of MA39170B1 publication Critical patent/MA39170B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La présente invention concerne des composés de formule (i) dans laquelle r1, x1, x2, x3 et x4 sont, tels que définis dans le présent document, des inhibiteurs de la protéine erk. L'invention concerne également des compositions et des procédés de traitement de troubles hyperprolifératifs.
MA39170A 2013-12-06 2014-12-03 Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer MA39170B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912905P 2013-12-06 2013-12-06
PCT/US2014/068452 WO2015085007A1 (fr) 2013-12-06 2014-12-03 Inhibiteurs de sérine/thréonine kinase

Publications (2)

Publication Number Publication Date
MA39170A1 MA39170A1 (fr) 2018-04-30
MA39170B1 true MA39170B1 (fr) 2019-05-31

Family

ID=52350292

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39170A MA39170B1 (fr) 2013-12-06 2014-12-03 Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer

Country Status (23)

Country Link
US (5) US9867833B2 (fr)
EP (1) EP3077401B1 (fr)
JP (2) JP6449293B2 (fr)
KR (1) KR102359759B1 (fr)
CN (1) CN106029672B (fr)
AR (1) AR098647A1 (fr)
AU (1) AU2014360455B2 (fr)
BR (1) BR112016012844B1 (fr)
CA (1) CA2932729C (fr)
CL (1) CL2016001368A1 (fr)
CR (1) CR20160309A (fr)
EA (1) EA031243B1 (fr)
IL (1) IL246017B (fr)
MA (1) MA39170B1 (fr)
MX (1) MX368443B (fr)
MY (1) MY176049A (fr)
PE (1) PE20160886A1 (fr)
PH (1) PH12016501071A1 (fr)
SG (1) SG11201604573WA (fr)
TW (1) TWI557126B (fr)
UA (1) UA120506C2 (fr)
WO (1) WO2015085007A1 (fr)
ZA (1) ZA201604461B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2909206A1 (fr) 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Inhibiteurs de la sérine/thréonine kinase
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
BR112016012844B1 (pt) 2013-12-06 2023-01-10 Genentech, Inc Composto e composições farmacêuticas
BR112016015236B1 (pt) * 2013-12-30 2023-11-14 Array Biopharma Inc. Composto, composições farmacêuticas, usos de um composto e método in vitro de inibição da atividade da proteína quinase erk
MX370906B (es) 2013-12-30 2020-01-09 Genentech Inc Inhibidores de serina/treonina cinasa.
MY197626A (en) 2015-11-09 2023-06-29 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2018012471A (es) 2016-04-15 2019-02-21 Genentech Inc Metodos de diagnostico y terapeuticos para el cancer.
AU2018329925A1 (en) 2017-09-08 2020-03-05 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
JP7433898B2 (ja) 2019-12-26 2024-02-20 キヤノン株式会社 光電変換素子、光電変換システム

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413751B2 (en) * 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
EP1931637A4 (fr) 2005-09-15 2009-09-16 Painceptor Pharma Corp Methodes permettant de moduler l'activite induite par la neurotrophine
AU2007337895C1 (en) * 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
DE602008003055D1 (de) * 2007-05-31 2010-12-02 Nerviano Medical Sciences Srl Zyklokondensierte Azaindole, die als Kinase-Hemmer wirken
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
WO2012118850A1 (fr) 2011-02-28 2012-09-07 Array Biopharma Inc. Inhibiteurs de sérine/thréonine kinase
WO2013020062A1 (fr) 2011-08-04 2013-02-07 Array Biopharma Inc. Composés de quinazoline utiles en tant qu'inhibiteurs de la sérine/thréonine kinase
EP2820009B1 (fr) 2012-03-01 2018-01-31 Array Biopharma, Inc. Inhibiteurs de sérine- ou thréonine-kinase
CN105143200B (zh) 2012-08-27 2018-10-16 阵列生物制药公司 用于治疗过度增殖性疾病的丝氨酸/苏氨酸激酶抑制剂
EP2909206A1 (fr) 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Inhibiteurs de la sérine/thréonine kinase
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
BR112016012844B1 (pt) 2013-12-06 2023-01-10 Genentech, Inc Composto e composições farmacêuticas
MX370906B (es) 2013-12-30 2020-01-09 Genentech Inc Inhibidores de serina/treonina cinasa.
BR112016015236B1 (pt) 2013-12-30 2023-11-14 Array Biopharma Inc. Composto, composições farmacêuticas, usos de um composto e método in vitro de inibição da atividade da proteína quinase erk
AU2015245743B2 (en) 2014-04-09 2020-09-24 Genentech, Inc. Process for the manufacturing of medicaments

Also Published As

Publication number Publication date
US10278975B2 (en) 2019-05-07
WO2015085007A1 (fr) 2015-06-11
US10842799B2 (en) 2020-11-24
ZA201604461B (en) 2022-05-25
JP2016539153A (ja) 2016-12-15
AU2014360455A1 (en) 2016-07-07
UA120506C2 (uk) 2019-12-26
BR112016012844B1 (pt) 2023-01-10
NZ721361A (en) 2021-07-30
US20200078371A1 (en) 2020-03-12
CA2932729C (fr) 2021-02-23
PE20160886A1 (es) 2016-09-14
JP6449293B2 (ja) 2019-01-09
SG11201604573WA (en) 2016-07-28
US11376260B2 (en) 2022-07-05
IL246017A0 (en) 2016-08-02
KR20160093703A (ko) 2016-08-08
CN106029672A (zh) 2016-10-12
MX368443B (es) 2019-10-02
US20150182537A1 (en) 2015-07-02
AR098647A1 (es) 2016-06-01
US20190192534A1 (en) 2019-06-27
US9867833B2 (en) 2018-01-16
US10517878B2 (en) 2019-12-31
BR112016012844A2 (fr) 2017-08-08
EA031243B1 (ru) 2018-12-28
CR20160309A (es) 2016-08-25
IL246017B (en) 2019-10-31
US20180000833A1 (en) 2018-01-04
MX2016007352A (es) 2016-09-08
TW201522338A (zh) 2015-06-16
EP3077401B1 (fr) 2018-04-18
US20210106593A1 (en) 2021-04-15
TWI557126B (zh) 2016-11-11
PH12016501071B1 (en) 2016-07-25
EA201691177A1 (ru) 2016-10-31
CN106029672B (zh) 2019-03-29
JP2019034970A (ja) 2019-03-07
CL2016001368A1 (es) 2016-12-09
MA39170A1 (fr) 2018-04-30
AU2014360455B2 (en) 2018-05-10
EP3077401A1 (fr) 2016-10-12
PH12016501071A1 (en) 2016-07-25
CA2932729A1 (fr) 2015-06-11
MY176049A (en) 2020-07-22
KR102359759B1 (ko) 2022-02-09

Similar Documents

Publication Publication Date Title
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EA201792529A1 (ru) Ингибиторы тирозинкиназы
NZ700928A (en) Dna-pk inhibitors
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
MA34797B1 (fr) Hétéroaryles et leurs utilisations
EA201790818A1 (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA35895B1 (fr) Inhibiteurs d'iap
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
MA38925B1 (fr) Dérivés de phénylalanine substitués
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
MA34098B1 (fr) Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
EA201591180A1 (ru) Составы ингибитора lfa-1
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
MA38591A1 (fr) Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b